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ess: fsfram@yahoo.co.uSummary Objectives: To determine the efficacy of oral theophylline compared
with placebo in people with stable chronic obstructive pulmonary disease (COPD).
Methods: Systematic review of randomized-controlled trials comparing oral
theophylline with placebo for a minimum of 7 days in people with stable COPD.
Results: Twenty randomized-controlled trials were included in this review. The
following outcomes showed significant improvement with theophylline compared with
placebo: FEV1 and FVC both improved with theophylline (weighted mean difference
[WMD] 0.10 L; 95% confidence interval [95% CI] 0.04–0.16 and WMD 0.21L; 95% CI
0.10–0.32, respectively). VO2 max also improved with theophylline (WMD 195.27mL/
min; 95% CI 112.71–277.83), as did PaO2 and PaCO2 (WMD 3.18mmHg; 95% CI 1.23–5.13
and WMD 2.36mmHg; 95% CI 3.52 to 1.21, respectively). Patients preferred
theophylline over placebo (relative risk 2.27; 95% CI 1.26–4.11). Theophylline
increased the risk of nausea compared with placebo (RR 7.67; 95% CI 1.47–39.94).Elsevier Ltd. All rights reserved.
been cited in this evidence-based review: Ram FS, Jones PW, Castro AA, et al. Oral theophylline
sease. The Cochrane Library, Issue 4, 2002. Copyright Cochrane Library, reproduced with
k (F.S.F. Ram).
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F.S.F. Ram et al.136Conclusion: This review has shown that theophylline still has a role in the
management of stable COPD, and is preferred by patients over placebo. However, the
benefits of theophylline in stable COPD have to be weighed against the risk of adverse
effects.
& 2004 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is,
by definition, characterized by limited reversibility
with bronchodilator therapy.1,2 Patients often have
major limitations of physical activity, especially
breathlessness during exercise. Oral theophylline is
a bronchodilator that has been used for many
years, although sympathomimetic and inhaled
anticholinergic agents are now used more often.3
Despite this change in prescribing pattern, there is
still a perception that theophylline confers addi-
tional benefit over that produced by the newer
agents.4
Theophylline has shown benefit in the manage-
ment of asthma in both children 5 and adults,6 but
its role in the management of COPD has not been
fully defined. Studies have not consistently shown
theophylline to be beneficial in the management of
stable COPD.7–9 The British Thoracic Society10
guidelines on management of COPD recommends
use of xanthine derivatives as a last resort, and only
after all other treatments have failed to show a
response. The American Thoracic Society1 guideline
on COPD makes stronger recommendations for the
use of theophylline in both stable and acute
management of COPD but, because of its narrow
therapeutic index, it also recommends cautious
use.11 Owing to the increasing number of guidelines
on the management of COPD, and the lack of
evidence-based documentation, the US National
Heart Lung and Blood Institute and the World
Health Organization have jointly developed evi-
dence-based guidelines for the management of
COPD, known as the Global Initiative for Chronic
Obstructive Lung Disease or GOLD.12,13 The GOLD
guideline recommends the use of theophylline as a
second-line option, because many studies have
shown its bronchodilator and non-bronchodilator
effectiveness in the management of stable COPD
(web address: www.goldcopd.com).
Most trials of oral theophylline in people with
COPD have used small numbers of participants. To
better evaluate the recommendations from various
COPD guidelines and the different conclusions from
the many clinical trials, we conducted a systematic
review of the literature in order to provide a
clearer picture of the efficacy of oral theophyllinein people with stable COPD. To our knowledge, no
other systematic review of the literature has been
published on the use of oral theophylline in stable
COPD. This systematic review was originally pub-
lished electronically in 2002 in the Cochrane
Library.14Materials and methods
Types of trials and participants
All included trials were randomized with crossover
designs that involved treatment with theophylline
or placebo. Trials could include people with any
degree of disease severity and lasted 7 days or
more. Only trials in people with stable COPD, as
defined by internationally accepted criteria,1,10,15
or defined objectively as a disorder characterized
by ‘‘reduced expiratory flow and slow forced
emptying of the lungs and features which do not
change markedly over several months’’,15 were
considered for inclusion.Search for trials
A search of the Cochrane database of clinical trials
was conducted up until and including April 2004,
with no language restrictions. We identified other
potential studies by writing to key authors,
examining bibliographies of all included studies
and relevant review articles. Titles and abstracts of
all of the trials identified by electronic searching
were assessed independently by two reviewers. The
full text copies of all potentially relevant trials
were obtained. Any disagreements between
reviewers were resolved with discussion.Methodological trial quality assessment
The methodological quality of all included trials
was assessed using two methods: the Cochrane
scale for assessment of allocation concealment,
and the Jadad16 quality grading, which evaluates
randomization, blinding and dropouts.
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Individual trial data were pooled using meta-
analytical technique where possible. For contin-
uous variables, the results of individual studies
were pooled using fixed-effect weighted mean
difference (WMD) or standardized mean difference
(SMD) with corresponding 95% confidence interval
(CI). The WMD is a meta-analytical technique used
to combine measures on continuous scales (such as
weight), where the mean, standard deviation and
sample size in each group is known. The weight
given to each study (e.g. how much influence each
study has on the overall results of the meta-
analysis) is determined by the precision of its
estimate of effect. In the statistical software used
in this review (RevMan), precision is equal to the
inverse of the variance. The WMD technique
assumes that all of the trials have measured the
outcome on the same scale. The SMD technique is
used when an outcome (such as symptom) is
measured in a variety of ways across studies (using
different scales), and it may not be possible to
combine study results in a systematic review. By
expressing the effects as a standardized value, the
results can be combined, as they have no units. SMD
is the difference between two means divided by an
estimate of the within-group standard deviation.
Where results were expressed as dichotomous
variables, relative risk (RR) with 95% CI was
calculated. RR is defined as the ratio of risk in the
intervention group to the risk in the control group.
An RR of one indicates no difference between
comparison groups. For all pooled effects, a test for
heterogeneity was carried out using the DerSimo-
nian and Laird method17, and a Po0.05 was
considered statistically significant.Results
Search for trials
From 310 abstracts, 86 full-text papers were
retrieved for closer assessment. Twenty-four trials
were selected for inclusion. Four trials were
multiple publications of the same cohort of
patients; therefore, 20 trials were included in the
review. Fig. 1 provides details on trial selection.
Characteristics of included participants and
concomitant medication
All studies included adults with COPD. COPD was
defined using objective criteria of less than 15% inFEV1 reversibility after inhaling a bronchodilator in
six studies3,9,18–21 or 25% in two studies.22,23 The
Medical Research Council definition of COPD was
used in two studies,18,24 and the American Thoracic
Society definition in one.25 One study26 did not
include patients who had a greater than 20% change
in either FEV1 or FVC over the previous 2 years.
Most of the studies also used a pre-defined criteria
based on predicted FEV1 or FEV1/FVC ratio for
including patients in their study; typical values for
FEV1 were less than 60–70% and, for FEV1/FVC
ratio, it was less than 0.6–0.7. One study25 included
patients with a post-bronchodilator FEV1/FVC ratio
of less than 70%. All of the studies included patients
who were either ex- or current smokers, and
excluded patients who had asthma. Baseline mean
FEV1 for the patients in the 20 studies ranged from
0.96–1.15 L. Mean age ranged from 58–69 years.
Four of the studies did not allow use of
bronchodilators during the study period.7,9,23,26
Twelve studies permitted use of regular bronchodi-
lators and inhaled corticosteroids for the duration
of the study period.3,18,19,24,25,27–33 Four studies did
not describe concomitant medication use.20–22,34Efficacy measurements
Thirteen studies with 244 patients contributed data
towards FEV1, which showed significant improve-
ment of 100 L with theophylline (WMD 0.10 L; 95%
CI ¼ 0:0420:16) (Fig. 2). Eleven trials with 196
patients contributed data towards FVC, which
showed a significant improvement of 210 L with
theophylline (WMD 0.21 L; 95% CI ¼ 0:1020:32)
(Fig. 3). FVC reported as percent predicted by
three studies also improved with theophylline
(WMD 3.93% predicted; 95% CI ¼ 0:2227:65). Six
studies with 156 patients reported arterial blood
gas tensions.3,7,9,19,27,31 Both PaO2 and PaCO2
showed significant improvements with theophylline
(WMD 3.18mmHg; 95% CI ¼ 1:2325:13 and WMD
2.36mmHg; 95% CI ¼ 3:52 to 1.21, respec-
tively) (Fig. 4 and 5).
Two studies with 32 patients reported VO2-
max,27,31 which showed significant improvement
with theophylline (WMD 195.27mL/min; 95%
CI ¼ 112:712277:83).
Two trials3,24 with 100 patients showed greater
preference for theophylline compared with placebo
(RR 2.27; 95% CI ¼ 1:2624:11). Three trials re-
ported data on nausea,3,7,31 with the risk of
experiencing nausea significantly increased with
theophylline (RR 7.67; 95% CI ¼ 1:47239:94).
Two studies with 58 patients18,23 reported
distance walked in 6min (WMD 33.38m; 95%
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Potentially relevant trials 
identified and screened for 
retrieval (n = 310) 
RCTs included in the meta-analysis (n = 
20) (four additional duplicate references 
for trials were already included)
RCTs retrieved for more detailed 
evaluation (n = 86) 
Potentially appropriate RCTs to be 
included in the meta-analysis (n = 
24)
RCTs or abstracts excluded as not 
relevant (n = 224) 
RCTs withdrawn by outcome, with 
reason (n = 0) 
RCTs with useable information by
outcome: 
FEV1 n = 13 
FVC n = 11 
FVC % predicted n = 3 
VO2max n = 2 
PaO2 n = 6 
PaCO2 n = 6 
Preference n = 2 
Nausea n = 3 
RCTs excluded with reason (n = 62) 
Not an RCT n = 11 
Not in patients with COPD n = 10 
Not in patients with stable COPD n = 4 
Mixed population of patients n = 1 
Inappropriate intervention n = 36 
Figure 1 Results of search for trials and reasons for excluding studies.
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patients19,22 reported distance walked in 12min
(WMD 26.90 m; 95% CI ¼ 8:93 to 62.74). In neither
group of studies was the effect significant, and,
when all four studies were combined using SMD, the
overall effect remained non-significant (SMD 0.30;
95% CI –0.01 to 0.62).
Two studies with 32 patients18,22 used the
100mm visual analogue scale to measure breath-
lessness (WMD 3.61mm; 95% CI ¼ 4:62 to 11.84).
In addition, these two studies18,22 reported symp-
toms of wheeze and dyspnoea using ordinal scales
(WMD 0.19; 95% CI ¼ 0:58 to 0.19 and WMD
0.32; 95% CI ¼ 0:84 to 0.25, respectively).
Other studies also reported symptom as outcomes
(e.g. dyspnoea, wheeze and quality of life).
However, owing to minimal data reporting and the
use of different methodologies, data from thesestudies could not be collated. Individual studies
did, however, report benefits. Alexander et al.7
used a six-point scale, which measured dyspnoea,
wheezing, cough, sputum, walking and feelings
that showed improvements in all categories
with the use of theophylline. Guyatt et al.23
reported significant improvements in dyspnoea and
quality-of-life scores. In addition, two trials18,22
reported modest improvement in dyspnoea,
another reported significant improvements in
dyspnoea scores,34 and two trials reported
improvements in wheezing and shortness of breath
with theophylline.26,30
Acute exacerbations was reported by two studies
with 45 patients,25,33 showing no significant differ-
ence between the theophylline and placebo group
(RR 0.33; 95% CI ¼ 0:1021:14). Unfortunately, no
data were reported on health status or mortality.
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Figure 2 Details of FEV1 (L). A square box indicates the mean value for each trial with the line through it representing
the 95% confidence interval. For this outcome, mean values left of the zero effect line (0) favours placebo and values on
the right favours theophylline. The solid diamond indicates the overall mean effect treatment has on FEV1. The Chi-
square value (0.94) and the degrees of freedom value (df ¼ 12) with a P value (P ¼ 1) at the bottom left of the graph
gives a measure of heterogeneity of the combined results that contributed data towards the overall mean result. The z-
statistic (3.44) with its P value (Po0:001) indicates the level of significance for the overall result.
Figure 3 Details of trials contributing data towards FVC (L).
Figure 4 Trials contributing data towards arterial oxygen tension at rest (PaO2 mmHg).
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Figure 5 Trials contributing data towards arterial carbon dioxide tension at rest (PaCO2 mmHg).
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This review has shown that orally administered
theophylline for a minimum duration of 7 days to
patients with moderate to severe stable COPD
improves lung function, ventilatory capacity and
arterial blood gas tensions. Although the risk of
adverse effects (nausea) was increased with theo-
phylline, patient preference for theophylline was
greater than placebo.
The magnitudes of the observed lung function
changes are relatively small, and there must be
doubt that these alone can explain the large
changes reported by individual patients with COPD
often treated with theophylline for symptom relief
(e.g. breathlessness). Meaningful symptomatic re-
sponses from bronchodilators in the presence of
trivial changes in FEV1 and FVC have previously
been reported.19,35,36 Unfortunately, few trials
included in this review reported symptoms. The
included trials that attempted to measure improve-
ments in symptoms (e.g. dyspnoea, quality of life
or wheeze) all showed improvements, but, owing to
minimal data reporting and the use of different
methodologies, data could not be collated. Indivi-
dual studies did, however, report benefits.
Other mechanisms have been proposed to explain
how theophylline might improve symptoms or
reduce breathlessness in patients with COPD.
Chrystyn et al.18 measured the effects of theophyl-
line on 33 patients with stable COPD. In their study,
a dose of theophylline that resulted in serum
concentrations of 15–20 mg/mL led to a small
increase in FEV1 of 13% (130mL), but a significant
64% decrease in trapped gas volume (1.84–0.67 L).
Unfortunately, this was the only study to report
data on trapped gas volume, and further trials are
needed.
Other investigators have shown that inhaled b2-
agonists and ipratropium bromide reduce exer-
tional breathlessness in people with stable COPD,and this correlates strongly with decreases in
thoracic gas entrapment18,37 and dynamic hyperin-
flation.38,39 The improvements in lung function
seen with theophylline in this review may be
caused by dilatation of the small airways, with a
consequent reduction in gas trapping. A fall in
trapped gas volume and thus functional residual
capacity is likely to improve the mechanical
advantage of the diaphragm and chest wall
muscles, and may well explain many of the
reported effects of theophylline on the respiratory
muscles.40
Theophylline has also been shown to increase
diaphragmatic strength.28,41 Its effect has been
shown to be greater in a fatigued diaphragm,40 a
phenomenon seen in severe COPD. In one trial,
theophylline increased trans-diaphragmatic pres-
sure by 16%, and this increase persisted even after
30 days of treatment with theophylline.40 In
therapeutic doses, theophylline is also known to
increase respiratory drive independent of
its effect on lung function.42 Theophylline
has also been known to increase respiratory muscle
function in normal people43 and in people with
COPD,41 as measured by increases in maximal
inspiratory and expiratory pressures. It has also
been suggested that theophylline reduces
breathlessness by improving diaphragmatic
contractility. Murciano et al.9 demonstrated an
improvement in respiratory muscle performance,
as indicated by a decline in the ratio of inspiratory
pleural pressure during quiet breathing to the
maximal pleural pressure.
Another interpretation is that the improvement
in respiratory muscle function is caused by an
improvement in the length-tension relationship of
the diaphragm because of the reduction in gas
trapping, and not because of an increase in
diaphragmatic contractility. A recent study by
Hatipoglu et al.44 supports this interpretation.
These mechanisms may be responsible for the
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seen with theophylline in this review.
Significant improvements were observed in ar-
terial blood gas tensions in patients treated with
theophylline. In severe cases of COPD, respiratory
rate is increased, and this may be combined with
shallow breathing that is pronounced by carbon
dioxide retention. It is known that theophylline
improves minute ventilation in humans45 and
animals,46 and also alters the ventilatory response
in COPD seen as improved ventilatory capacity
measured as increased VO2max. This ventilatory
response results in an increase in tidal volume,
which may be responsible for the improvement
seen in blood gas tensions. The increase in VO2 max
and the improved blood gas tensions could be
related either to a direct positive inotropic effect
of theophylline on the respiratory muscles28,47–49 or
to theophylline’s action via a central stimulatory
pathway,50,51 or to both. It is known that theophyl-
line is capable of stimulating the medullary
respiratory centre.52
Although only two studies provided data for VO2
max, this is an important significant finding, as
greater exercise performance is implied by in-
creases in VO2 max. Unfortunately, insufficient
studies provided data on exercise performance
(distance walked, cycle endurance or progressive
cycle ergometry) to permit us to relate the increase
in VO2 max to exercise performance.
Theophylline has a narrow therapeutic index,
and adverse effects are common even when serum
concentrations are in the therapeutic range of
10–20 mg/mL. In this review, significantly more
patients treated with theophylline compared with
placebo reported nausea. More serious adverse
effects of theophylline (e.g. supraventricular ar-
rhythmias53,54) were not found in this review.
Nevertheless, the benefits of theophylline in stable
COPD have to be weighed against the risk of
adverse effects. All of the studies included in this
review used target theophylline concentrations
within the usual therapeutic range. In patients
with asthma, theophylline exerts beneficial effects
at serum concentrations lower than the traditional
therapeutic range of 10–20 mg/mL.55,56 Lower con-
centrations of theophylline have the advantage
that they are associated with fewer adverse
effects. In future trials of theophylline in stable
COPD, it may be appropriate to have a lower serum
target concentration. An alternative approach
would be to study specific inhibitors of type IV
phosphodiesterases, which are reported to be
effective in the treatment of asthma but which
have fewer adverse effects compared with theo-
phylline.57–59Limitations of the review
The small numbers of patients in the included
studies, and incomplete reporting of results in the
published trials, made it difficult to derive firm
conclusions from the review. We wrote to included
study authors to obtain further data; however, the
response was limited.
There is also a pitfall in including crossover
studies, as the presence of carry-over effects of the
first treatment into the second treatment period
could lead to an underestimation of the real
difference among treatments.60 Nine of the studies
reported adequate washout periods between their
crossover arms ranging from 3 days to 2 weeks. The
remaining 11 studies did not have a washout period
or failed to report any washout period. A second
possible pitfall associated with crossover designs is
that the software we used (RevMan) forces us to
analyse crossover studies as if they were parallel
studies. It is known61 that the two methods give
identical results if the response to the two
treatments in the same individual is completely
unrelated, but parallel analysis may lead to
decreased statistical power compared with paired
analysis if the response to the two treatments is
positively correlated (i.e. if patients improving
during bronchodilator are also more likely to
improve somewhat during placebo). This possibility
cannot be discounted in our review. The results of
the statistical analysis from two-period crossover
trials make two main assumptions: no period effect
and no treatment-period interaction. But none of
the authors reported these findings (correlation
between the responses to the two treatments) from
their studies, and the presentation of the data did
not permit these types of analysis. Therefore, we
cannot exclude that our analysis underestimated
the statistical significance of the observed differ-
ences, compared with a paired analysis.Conclusions
This review confirms consistent benefit in improv-
ing lung function and arterial blood gas tensions in
people with COPD with and without adjuvant
bronchodilator therapy. These changes, while mod-
est, were associated with reports from individual
studies of improved breathlessness. The mechanism
of action of theophylline cannot be determined
from this review; however, it supports the actions
of theophylline as a ventilatory stimulant and as an
agent that reduces trapped gas, as well as a
bronchodilator. Despite an increase in adverse
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theophylline over placebo. With close monitoring of
individual patients, it seems that beneficial effects
may be obtained in individuals who remain sympto-
matic from COPD, despite first-line bronchodilator
therapy. Theophylline continues to have an im-
portant role in the management of symptomatic,
stable COPD, in accordance with the approach
suggested in recent COPD guidelines.1,10,13,15
Larger parallel, randomized-controlled trials
with explicit clinical and diagnostic criteria, suffi-
cient duration of follow-up and description of all
relevant clinical outcome measures are warranted.
Many previously conducted studies have relied
heavily on the readily available physiological
measurements (e.g., FEV1, FVC, PEFR). These
outcomes are not particularly sensitive measures
of change in this group of patients,36,62 and we
suggest that other relevant outcome measures
should be used (e.g., trapped gas volume, symp-
toms, health status, adverse effects, exercise
capacity and exacerbations). Future studies should
also endeavour to define which ‘‘types’’ of patients
are most likely to respond to treatment with
theophylline. Studies also need to examine the
role of theophylline in comparison, and in conjunc-
tion, with newer agents such as long-acting
bronchodilators. Further investigation of the effect
of theophylline on ventilatory mechanics would be
helpful to delineate the non-bronchodilator effects
of theophylline, which seem to be important.
Because of a lower incidence of adverse effects,
it will be interesting to observe the efficacy of
specific inhibitors of type IV phosphodiesterases in
people with COPD.
Practice points
 Oral theophylline remains an important
option in the management of stable COPD.
 Theophylline improves lung function, arter-
ial blood gas tensions and ventilatory capa-
city.
 Patients prefer theophylline to placebo.
 Benefits of theophylline in stable COPD have
to be weighed against the risk of adverse
effects.Research directions
 Sensitive measures of change in COPD trials
are required.
 There is a need to identify types of COPD
patients that are most likely to respond to
treatment with theophylline. There is a need to examine the role of
theophylline in comparison, and in conjunc-
tion, with newer agents such as long acting
bronchodilators.
 It is important to delineate the non-bronch-
odilator effects of theophylline.Acknowledgements
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